Canaccord initiated coverage of BridgeBio with a Buy rating and $104 price target. The firm is "bullish as ever" on the transthyretin amyloid cardiomyopathy space. Canaccord cites BridgeBio's continued launch progress with Attruby and its three other rare disease launches coming in the next 12-18 months for the Buy rating. The firm is also bullish on infigratinib in achondroplasia, citing the drug's "strong efficacy, clean safety," and oral route of administration versus the once daily or weekly injections from competitors.
